News
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...
Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...
TipRanks on MSN4h
Insmed downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor downgraded Insmed (INSM) to Equal Weight from Overweight with a price target of $126, up from $112. The ...
Stocktwits on MSN9h
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback